A Giant Leap in India’s Fight Against Dengue: Phase 3 Vaccine Trial Launched

▴ A Giant Leap in India’s Fight Against Dengue
This trial not only aims to protect the population but also reinforces India’s capability to produce cutting-edge healthcare solutions, furthering the nation’s goal of self-reliance in essential medical innovations.


The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched India's first Phase 3 clinical trial for a dengue vaccine, marking a significant milestone in the nation’s healthcare sector. This trial, focused on evaluating the effectiveness of DengiAll, a tetravalent dengue vaccine developed indigenously by Panacea Biotec, began on Wednesday at PGIMS Rohtak.

Union Health Minister J P Nadda described this initiative as a pivotal step in India’s ongoing efforts to combat dengue. He emphasized that this collaboration between ICMR and Panacea Biotec not only aims to safeguard public health but also aligns with the broader vision of Atmanirbhar Bharat, which seeks self-reliance in critical areas like healthcare.

Dengue remains a formidable challenge in India, as the country currently lacks any specific antiviral treatment or licensed vaccine for the disease. The complex nature of dengue, caused by four distinct virus serotypes, has made vaccine development particularly challenging. India is among the nations with the highest incidence of dengue, with the World Health Organization (WHO) noting a consistent rise in global cases over the past two decades.

DengiAll, the vaccine being tested, is based on a tetravalent strain initially developed by the U.S. National Institutes of Health. Panacea Biotec is one of three Indian companies that received this strain, and after extensive research and successful Phase 1 and 2 trials completed between 2018 and 2019, the company is now moving forward with this crucial Phase 3 trial.

The current trial, a joint effort between ICMR and Panacea Biotec, will be conducted across 19 sites in 18 States and Union Territories of India. It will involve over 10,335 healthy adult participants, who will be monitored over a two-year period. This trial is predominantly funded by ICMR, with additional support from Panacea Biotec, underscoring the commitment to advancing indigenous vaccine development.

Dr. Rajesh Bhushan, Secretary of the Department of Health and Family Welfare, highlighted the trial's significance, stating that it represents a major stride in addressing one of India’s most urgent public health issues. He also pointed out that this initiative reflects the country’s dedication to self-reliance in healthcare and the development of homegrown solutions.

Dengue poses a significant public health threat in India, with the country ranking among the top 30 globally in terms of disease incidence. According to WHO data, the incidence of dengue has been rising steadily worldwide, with more than 129 countries reporting cases by the end of 2023.

In India, a substantial proportion of dengue infections—between 75% and 80%—are asymptomatic, meaning that many people who carry the virus do not show symptoms but can still spread the disease through Aedes mosquito bites. Among those who do exhibit symptoms, children are particularly vulnerable, facing a higher risk of severe illness and hospitalization.

For adults, dengue can progress to severe forms like dengue hemorrhagic fever and dengue shock syndrome, both of which are potentially fatal. The presence of four dengue virus serotypes complicates the situation further, as individuals can be reinfected by different serotypes, with limited cross-protection between them.

As India advances in this critical Phase 3 trial, the hope is that DengiAll will soon become a key tool in the nation’s fight against dengue, offering a much-needed preventive measure against this widespread and dangerous disease. This trial not only aims to protect the population but also reinforces India’s capability to produce cutting-edge healthcare solutions, furthering the nation’s goal of self-reliance in essential medical innovations.

Tags : #dengue #vaccine #ICMR

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

GET WEDDING-READY WITH KAY BEAUTY: KATRINA KAIF’S TOP PICKS FOR BRIDES & BRIDESMAIDSNovember 11, 2024
Amrita Vishwa Vidyapeetham Students Win Global All-Track Grand Prize at HackHarvard 2024 Organized by Harvard University StudentsNovember 11, 2024
Algorand Foundation Announces its Investment in 5 Startups from the Inaugural Startup Lab Program at T-HubNovember 11, 2024
DOST, DTI & DICT join forces for Philippine Startup Week 2024 to Ignite Filipino InnovationNovember 11, 2024
Firewall gender equality from threats like anti-rights Geneva Consensus DeclarationNovember 11, 2024
Delhi’s Air Crisis: How Toxic Air and Pollution Are Still Threatening Health and Life QualityNovember 11, 2024
Are You at Risk? AI Data Exposes Unseen Triggers of Diabetes in Our EnvironmentNovember 11, 2024
Why Children in High-Risk Areas Are Paying the Price for TB Neglect?November 11, 2024
The Deadly 17: WHO’s Vaccine Priority List to Tackle Life-Threatening InfectionsNovember 09, 2024
Is Your Gut Telling You Something? The Bacterial Clues to Early Rheumatoid ArthritisNovember 09, 2024
Newcastle University Announces VC Excellence Scholarships for Undergraduate and Postgraduate StudiesNovember 08, 2024
Beyond the X-ray: Celebrating the Pioneers of Radiography on World Radiography DayNovember 08, 2024
Digital Doctors and Village Heroes: Tackling Depression and Stigma in India’s HeartlandNovember 08, 2024
Why Are Food Giants Pushing ‘Low-Star’ Nutrition on Low-Income Countries?November 08, 2024
NokAir joins hands with Çelebi for world class ground handling services for newly launched Bangkok-Mumbai routeNovember 07, 2024
Why Are Rare Disease Patients Paying a Fortune When Local Production Could Save Lives?November 07, 2024
Building Lips in the Lab: How Scientists Are Growing Lab Lips to Heal and RebuildNovember 07, 2024
National Cancer Awareness Day: How Small Changes Today Can Save Lives TomorrowNovember 07, 2024
Introducing an AI tool for accurate diagnosis of cholelithiasis on abdominal CT scansNovember 06, 2024
Nat Habit Unveils New Chapter of “Breathe Life Into Your Beauty” Campaign championed by Content Creators and the Launch of VeDHA, digital skin analysis toolNovember 06, 2024